linjc16/ctgov huggingface dataset:
Solid Tumors in RASopathies

Study Overview
=================
Brief Summary
-----------------
RASopathies are a group of syndromes, caused by variants of genes involved in the regulation of the Ras/MAP/ERK pathway. This intracellular transduction pathway profoundly affects embryogenic development, organogenesis, synaptic plasticity and neuronal growth. RASopathies are characterized by multi-organ involvement, growth delay, premature aging and haemato-oncological manifestations. Based on evidences provided by literature, cancer screening protocols are applied in some individuals affected by RASopathies, even though detailed information about prevalence and molecular pathogenesis of such tumors is still not clearly elucidate.

Detailed Description
-----------------
To define the prevalence of solid (non-haematological) neoplasms in a monocentric cohort of patients affected by RASopathies To perform Next Generation Sequencing (NGS) analysis on tissue samples to preliminarily characterize the molecular pathogenesis of solid tumors in these patients' categories.

Official Title
-----------------
Incidence and Molecular Pathogenesis of Solid Tumors in RASopathies

Conditions
-----------------
RASopathy, Costello Syndrome, Cardio-Facio-Cutaneous Syndrome, Noonan Syndrome

Intervention / Treatment
-----------------
* Diagnostic Test: Molecular characterization of solid tumor in RASopathies


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical and molecularly confirmed diagnosis of a RASopathy Exclusion Criteria: Clinical diagnosis of RASopathy without molecular characterization
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Case group<br>To report the prevalence of solid tumors in a monocentric cohort of individuals with RASopathies | Diagnostic Test: Molecular characterization of solid tumor in RASopathies<br>* NGS analysis on tumor sample<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of solid tumors in RASopathies | To detect prevalence of solid tumors in monocentric cohort of RASopathies | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Molecular characterization of solid tumors in RASopathies | NGS analysis on tumor tissue samples | 5 years |
Different Administration Routes of Dexmedetomidine on Postoperative Delirium

Study Overview
=================
Brief Summary
-----------------
Intravenous dexmedetomidine has been reported to decrease the occurrence of postoperative delirium (POD) in elderly patients. Nevertheless, some previous studies have indicated that intratracheal dexmedetomidine and intranasal dexmedetomidine are also effective and convenient. The current study aimed to compare the effect of different administration routes of dexmedetomidine on POD in elderly patients.

Official Title
-----------------
Effect of Different Administration Routes of Dexmedetomidine on Postoperative Delirium in Elderly Patients Undergoing General Anesthesia

Conditions
-----------------
Dexmedetomidine, Postoperative Delirium, General Anesthesia

Intervention / Treatment
-----------------
* Drug: Dexmedetomidine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Older than 65 years; General anesthesia for more than two hours; Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intranasal dexmedetomidine<br> | Drug: Dexmedetomidine<br>* Different Administration Routes of Dexmedetomidine<br>|
| Active Comparator: Intravenous dexmedetomidine<br> | Drug: Dexmedetomidine<br>* Different Administration Routes of Dexmedetomidine<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The frequency of delirium during the first 3 postoperative days |  | 3 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidence of postoperative sore throat |  | 3 days | 
| The incidence of sleep quality |  | 3 days |
Reminder Messages for Lung Cancer Screening

Study Overview
=================
Brief Summary
-----------------
To test lung cancer screening reminder messages to help adults who 1) 50 to 80 years of age, 2) smoke or have smoked, and 3) do not have history of lung cancer by self-report.

Detailed Description
-----------------
Primary Objectives: -In this project we will develop, refine, and test reminders for LCS to ensure they are acceptable to patients who have a history of cigarette use.

Official Title
-----------------
Reminder Messages for Lung Cancer Screening

Conditions
-----------------
Skin Flaps, Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults ages 50-80 years Currently use cigarettes or have smoked in the past English or Spanish speaker (based on self-report) Exclusion Criteria: • History of lung cancer (based on self-report)

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ottawa Acceptability questionnaires | Score scale ranges Strongly agree Agree Neither agree nor disagree Disagree Strongly disagree | through study completion; an average of 1 year |
Single-cell Landscape of BALF in Patients With Severe ARDS and CARDS

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to learn about the effect of steroid therapy in patients with COVID-19 ARDS. The main questions it aims to answer are: Differences between patients with COVID-19 ARDS before and after steroid treatment in BALF single cell landscape, as well as patients with different prognosis. Differences between COVID-19 and non COVID-19 ARDS patients in BALF single cell landscape. Participants will Choose whether to use or not to utilize steroid treatment based on conditions.

Detailed Description
-----------------
Collect BALF from COVID-19 and non-COVID-19 ARDS patients both before and during remission, then perform single-cell sequencing.

Official Title
-----------------
Single-cell Landscape of BALF in Patients With Severe ARDS and CARDS: an Analysis of the Effectiveness of Steroid Therapy and a Comparison Between COVID-19 ARDS and ARDS From Other Etiologies

Conditions
-----------------
ARDS: Acute Respiratory Distress Syndrome, Covid19

Intervention / Treatment
-----------------
* Drug: steroid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Severe ARDS patients Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COVID-19 with steroid<br>COVID-19 ARDS patients with steroid treatment | Drug: steroid<br>* Moderate- or high-dose steroids<br>|
| COVID-19 without steroid<br>COVID-19 ARDS patients without steroid treatment | |
| non-COVID-19 with steroid<br>non-COVID-19 ARDS patients with steroid treatment | Drug: steroid<br>* Moderate- or high-dose steroids<br>|
| non-COVID-19 without steroid<br>non-COVID-19 ARDS patients without steroid treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| single-cell analysis in BALF before treatment | collect BALF before and during treatment and perform single-cell sequencing | before treatment in ICU | 
| single-cell analysis in BALF after treatment | collect BALF before and during treatment and perform single-cell sequencing | After treatment in ICU for 1-4 weeks |
Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

Study Overview
=================
Brief Summary
-----------------
The study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants.

Official Title
-----------------
A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

Conditions
-----------------
Intestinal Malabsorption

Intervention / Treatment
-----------------
* Drug: ELGN-2112
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female pre-term infant 26 and up to 32 weeks gestation. Gestational age matching (±2 weeks) between maternal dates and/or early antenatal ultrasound Birth weight ≥ 500g Singleton or twin birth Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 5 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: ELGN-2112<br> | Drug: ELGN-2112<br>* Human insulin [rDNA]<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Numbers of days to achieve full enteral feeding |  | 28 days or discharge from hospital |
Suhexiang Pill for Acute Ischemic Stroke: A Registry Study

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this study is to investigate the effectiveness and safety of the Suhexiang Pill for patients with acute ischemic stroke in real-world settings.

Detailed Description
-----------------
Suhexiang Pill, a traditional Chinese patent medicine, is widely used in China for acute stroke. However, there is a lack of evidence of its efficacy and safety for acute ischemic stroke in real-world setting. This registry study will recruit 1000 patients who receive Suhexiang Pill treatment after acute ischemic stroke.

Official Title
-----------------
Suhexiang Pill for Acute Ischemic Stroke: A Prospective Registry Study of Real-world Data

Conditions
-----------------
Ischemic Stroke

Intervention / Treatment
-----------------
* Drug: Suhexiang Pill


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute ischemic stroke within 7 days of symptom onset. Age ≥ 18 Patient who has received Suhexiang Pill treatment Patient or legally authorized representative has signed informed consent. Exclusion Criteria: Be allergic to Suhexiang Pill Known to be pregnant or breastfeeding. With conditions that render outcomes or follow-up unlikely to be assessed.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Suhexiang Pill|Suhexiang Pill is an approved traditional Chinese patent medicine.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients independent | Proportion of patients independent is defined as the modified Rankin Scale score of 0, 1, or 2. | 90 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| National Institute of Health Stroke Scale | The National Institute of Health Stroke Scale (NIHSS) ranges from 0 to 42, with higher scores indicating more severe neurological deficits. | The change from baseline to day 10 or discharge. | 
| Glasgow Coma Scale | The Glasgow Coma Scale (GCS) is used to describe the extent of impaired consciousness in all types of acute medical and trauma patients, ranging from 0 to 15, with lower scores indicating more severe impaired consciousness. | The change from baseline to day 10 or discharge. | 
| Patient reported outcome | The patient reported outcome (PRO) scale of stroke consists of four dimensions including the influence on physical, emotional, and social functioning, as well as the overall satisfaction with treatment. | At day 10 or discharge. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute ischemic stroke, traditional Chinese medicine, registry study
Nanoparticles in Blood: Understanding and Controlling Protein Corona for Optimized Nanomedicine

Study Overview
=================
Brief Summary
-----------------
The main objective is to study the effect of engineered nanoparticles SPIONs (superparamagnetic iron oxide) on hemostasis. Nanoparticles will be incubated in blood and platelet aggregation will be measured. In parallel, nanoparticles will also be incubated in blood and then plasma proteins adsorbed on them will be separated and analyzed. The proteins found on the nanoparticles will be linked to the platelet aggregation observed to help developing innovative protein functionalized nanoprobes for optimized nanomedicine.

Official Title
-----------------
Nanoparticles in Blood: Understanding and Controlling Protein Corona for Optimized Nanomedicine

Conditions
-----------------
Coagulation Tests

Intervention / Treatment
-----------------
* Other: blood tests


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all people Exclusion Criteria: patient under 18 years old, legal protection measure, pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients from intensive care units<br>patients with hemostasis disorders (coagulation and/or platelets), antiplatelet and/or anticoagulant treatment | Other: blood tests<br>* evaluate the possible impact of iron oxide nanoparticles (superparamagnetic iron oxide = SPIONs) (N=10) in the blood circulation;<br>|
| controls<br>healthy people | Other: blood tests<br>* evaluate the possible impact of iron oxide nanoparticles (superparamagnetic iron oxide = SPIONs) (N=10) in the blood circulation;<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| impact of nanoparticles on coagulation tests ou platelet functions |  | at the baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference of behaviour of the nanoparticles (N=10 preparations) on coagulation cascade and platelet functions |  | at the baseline |
Lung Tumor Protein Synthesis Rates in Lung Cancer Patients

Study Overview
=================
Brief Summary
-----------------
The current study will recruit lung cancer patients to measure tissue protein synthesis rates of non-small cell lung carcinomas and healthy lung tissue. The protein synthesis rates of healthy lung tissue will be compared to lung tumor tissue to establish the remodeling characteristics of healthy versus cancerous lung tissues. We will also examine whether tissue protein synthesis rates of non-small cell lung carcinomas are associated with various tumor- (i.e., size, subclassification) and patient-derived (i.e., inflammation, lung function, smoking status, and smoking history) parameters.

Official Title
-----------------
Characterizing Tissue Protein Synthesis Rates of Non-small Cell Lung Carcinomas in Lung Cancer Patients

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Other: There are no interventions in the present study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 18-65 years Compos mentis Diagnosed with lung cancer, with treatment requiring a thoracotomy or VATS lobectomy Exclusion Criteria: Neoadjuvant chemo- or radiotherapy in the past four weeks Use of systemic steroids in the past four week Insulin-dependent diabetes mellitus Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lung cancer patient<br>Lung cancer patients diagnosed a non-small cell lung carcinoma requiring resection surgery. | Other: There are no interventions in the present study<br>* There are no interventions in the present study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lung tumor fractional synthetic rate | units: % per day | 5 days prior to surgery | 
| Lung tissue fractional synthetic rate | units: % per day | 5 days prior to surgery | 
| Muscle tissue fractional synthetic rate | units: % per day | 5 days prior to surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma glucose concentrations | units: mmol/L | Baseline | 
| Plasma insulin concentrations | units: pmol/L | Baseline | 
| Plasma GH concentrations | units: mU/L | Baseline | 
| Plasma IGF-1 concentrations | units: nmol/L | Baseline | 
| Plasma IGFBP-1 concentrations | units: ug/L | Baseline | 
| Plasma IGFBP-3 concentrations | units: ug/L | Baseline | 
| Plasma CRP concentrations | units: mg/L | Baseline | 
| Plasma IL-1 concentrations | units: ng/L | Baseline | 
| Plasma IL-6 concentrations | units: ng/L | Baseline | 
| Plasma IL-10 concentrations | units: ng/L | Baseline | 
| Plasma TNF-alpha concentrations | units: ng/L | Baseline |
Alisklamp and Dorsal Slit Sleeve Circumcision

Study Overview
=================
Brief Summary
-----------------
In this study the plan is to compare the circumcision performed with Alisklamp versus Dorsal Slit Sleeve method in terms of age, co-existing health conditions, surgery time, recovery period, tissue edema and bleeding, postoperative infection, wound healing, wound dehiscence, skin tunnel, and overall complications.

Detailed Description
-----------------
The study compares two circumcision techniques in children: the dorsal sleeve slit method and the alisclamp method. The dorsal sleeve slit technique, conducted under local anesthesia for about 20-30 minutes, involves cutting the penile skin dorsally, removing excess skin and prepuce, and suturing with 5/0 vicryl. The alisclamp method, also under local anesthesia, entails retracting the penile skin, placing a clamp, excising excess prepuce, and sending the patient home. The clamp is removed after 48 hours without anesthesia, with the total procedure lasting under 5 minutes. This research assesses these methods based on factors like age, co-existing health conditions, surgery time, recovery period, tissue edema and bleeding, postoperative infection, wound healing, wound dehiscence, skin tunnel, and overall complications.

Official Title
-----------------
Comparison of Alisklamp and Dorsal Slit Sleeve Circumcision: A Randomized Controlled Trial

Conditions
-----------------
Circumcision

Intervention / Treatment
-----------------
* Device: Alisklamp
* Other: Dorsal slit circumcision technique


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male patients between 0-2 years and 6-18 years Exclusion Criteria: 2-6 years, several penil chordee, hypospadias, previous penil surgery

Ages Eligible for Study
-----------------
Minimum Age: 1 Minute
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Classical dorsal slit circumcision technique<br>In this group, the patients who will operated with dorsal sleeve slit circumcision technique. | Other: Dorsal slit circumcision technique<br>* In this group, included the patients who will operated with dorsal slit circumcision technique<br>|
| Experimental: Alisklamp<br>In this group, the patients who will operated with Alisklamp technique. | Device: Alisklamp<br>* Alisklamp<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Healing time | Healing time | 2 weeks | 
| infections | wound infections | 2 weeks | 
| wound dehiscence | wound dehiscence | 2 weeks | 
| skin tunnel | presense of the number of skin tunnel | 1 month |